Media coverage about IRIDEX (NASDAQ:IRIX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. IRIDEX earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.5293768830724 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of NASDAQ:IRIX traded down $0.33 during midday trading on Friday, hitting $8.82. 210 shares of the stock were exchanged, compared to its average volume of 11,700. The company has a market capitalization of $104.98 million, a PE ratio of -7.95 and a beta of 1.60. IRIDEX has a twelve month low of $4.28 and a twelve month high of $10.98.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings results on Thursday, August 2nd. The medical equipment provider reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. The business had revenue of $10.30 million during the quarter, compared to the consensus estimate of $9.21 million. IRIDEX had a negative return on equity of 51.61% and a negative net margin of 36.98%. equities analysts forecast that IRIDEX will post -1.14 EPS for the current year.

Separately, Zacks Investment Research upgraded shares of IRIDEX from a “sell” rating to a “hold” rating in a research report on Thursday, May 10th.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Further Reading: How Do Tariffs Affect Trade Balances?

Insider Buying and Selling by Quarter for IRIDEX (NASDAQ:IRIX)

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.